Moreover, the stable knockdown of SLC2A3/PGAM1 in CRC cells demonstrated a significant reduction in tumor volume and weight derived from p53‐WT cells compared with those from control‐treated cells, whereas the p53‐MT xenograft did not respond to the stable knockdown of SLC2A3/PGAM1 (Fig EV5J and K). This evidence concerns the gene TP53 and colorectal carcinoma.